Schering-Plough to ramp up neuroscience sales presence
This article was originally published in Scrip
Executive Summary
Schering-Plough is fortifying its US presence in neuroscience with a shake-up of its sales force structure. The firm will ramp up its sales team in the area as it nears regulatory approvals for its bipolar mania and schizophrenia candidate, Saphris (asenapine).